Experienced in Basal Cell Skin Cancer

Dr. April Salama

Hematology | Oncology
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
On Staff At
Offers Telehealth
Experienced in Basal Cell Skin Cancer
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I am a medical oncologist who specializes in the treatment of patients with skin cancer. I am part of a team of surgical oncologists, dermatologists, and radiation oncologists who all work together to determine the best treatment approach for each patient. My focus is on treating patients with advanced melanoma, as well as melanoma that is at high risk for recurrence after surgery. We also treat patients with merkel cell carcinoma and advanced basal cell and cutaneous squamous cell carcinoma. We also have a number of clinical trial options available, allowing our patients access to the newest therapies available.

Dr. Salama is rated as an Experienced provider by MediFind in the treatment of Basal Cell Skin Cancer. Her top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Posterior Fossa Tumor.

Her clinical research consists of co-authoring 104 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Fellowships
Hematology-Oncology, University of Chicago Medical Center (Illinois)
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Duke Cancer Center
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-681-6900

Additional Areas of Focus

Dr. Salama has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Enrollment Status: Terminated
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

104 Total Publications

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.
Journal: EClinicalMedicine
Published: May 14, 2025
View All 104 Publications
Similar Doctors
Diane L. Reidy-Lagunes
Experienced in Basal Cell Skin Cancer
Dr. Diane L. Reidy-Lagunes
Hematology Oncology | Hematology | Oncology
Experienced in Basal Cell Skin Cancer
Dr. Diane L. Reidy-Lagunes
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances

Diane Reidy-Lagunes is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Reidy-Lagunes is rated as an Elite provider by MediFind in the treatment of Basal Cell Skin Cancer. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.

Experienced in Basal Cell Skin Cancer
Dr. John T. Dorsey
Hematology Oncology | Hematology | Oncology
Experienced in Basal Cell Skin Cancer
Dr. John T. Dorsey
Hematology Oncology | Hematology | Oncology

The Moses H Cone Memorial Hospital Operating Corporation

501 N Elam Ave, 
Greensboro, NC 
 (49.9 miles away)
336-832-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Dorsey is a Hematologist Oncology specialist and a Hematologist in Greensboro, North Carolina. Dr. Dorsey is rated as an Experienced provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Nevoid Basal Cell Carcinoma Syndrome, Langerhans Cell Histiocytosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome. Dr. Dorsey is currently accepting new patients.

VIEW MORE BASAL CELL SKIN CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Salama's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Salama is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Melanoma of the Eye
    Dr. Salama is
    Elite
    . Learn about Melanoma of the Eye.
    See more Melanoma of the Eye experts
  • Distinguished
  • Metastatic Uveal Melanoma
    Dr. Salama is
    Distinguished
    . Learn about Metastatic Uveal Melanoma.
    See more Metastatic Uveal Melanoma experts
  • Posterior Fossa Tumor
    Dr. Salama is
    Distinguished
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Salama is
    Distinguished
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
  • Squamous Cell Skin Carcinoma
    Dr. Salama is
    Distinguished
    . Learn about Squamous Cell Skin Carcinoma.
    See more Squamous Cell Skin Carcinoma experts
  • Advanced
  • Breast Cancer
    Dr. Salama is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Salama is
    Advanced
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
  • Metastatic Brain Tumor
    Dr. Salama is
    Advanced
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Olfactory Neuroblastoma
    Dr. Salama is
    Advanced
    . Learn about Olfactory Neuroblastoma.
    See more Olfactory Neuroblastoma experts
  • Oral Squamous Cell Carcinoma
    Dr. Salama is
    Advanced
    . Learn about Oral Squamous Cell Carcinoma.
    See more Oral Squamous Cell Carcinoma experts
  • Paget Disease of the Breast
    Dr. Salama is
    Advanced
    . Learn about Paget Disease of the Breast.
    See more Paget Disease of the Breast experts
View All 9 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Salama is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Salama is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Alveolar Soft Part Sarcoma
    Dr. Salama is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anal Cancer
    Dr. Salama is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Autoimmune Hemolytic Anemia
    Dr. Salama is
    Experienced
    . Learn about Autoimmune Hemolytic Anemia.
    See more Autoimmune Hemolytic Anemia experts
  • Basal Cell Skin Cancer
    Dr. Salama is
    Experienced
    . Learn about Basal Cell Skin Cancer.
    See more Basal Cell Skin Cancer experts
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.